Healthcare

Popular Topics in Healthcare

Subscribe to Updates in Healthcare

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.

Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

Healthcare

The GLG Healthcare Practice provides access to a global network of more than 49,000 experts from across the entire healthcare industry including physicians, researchers, scientists, and healthcare industry executives.

The Healthcare Practice provides insight into issues affecting the pharmaceutical, biotechnology, medical device, and healthcare services sectors.

Leading Experts on Healthcare

What is a GLG Leader?

David Ziolkowski
Sr Vice President and Chief Information Officer
Sampson Regional Medical Center

David Ziolkowski is the Senior Vice President and Chief Information Officer at the Sampson Regional Medical Center located in Clinton, North Carolina. He manages over a dozen technical and non-technical departments within the hospital expanding his role to Senior Vice President, Support Services and...

John Waugh
Director of System Laboratory Operations
Henry Ford Health System

John Waugh is the Director of System Laboratory Operations at Henry Ford Health System in Detroit, the 12th largest US hospital laboratory, research & academic medical center. Mr. Waugh has expertise in new and emerging clinical and molecular diagnostic systems including products and services from Cepheid,...

Daniel Wynn, MD
Director, Clinical Research
Consultants In Neurology Ltd.

Daniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple sclerosis, Alzheimer's disease, stroke, chronic...

Samir Mehta, MD
Orthopaedic Surgeon
Hospital of the University of Pennsylvania - CC

Samir Mehta, MD, is an Orthopaedic Surgeon at the Hospital of the University of Pennsylavnia. Previously, he was an Instructor at Harborview Medical Center, and Orthopaedic Surgeon and Assistant Professor of Orthopaedic Surgery in the Division of Orthopaedic Trauma at the University of Pennsylvania...

David Mandel, MD
Physician
Mandel, David R Md

David Mandel, MD, is a rheumatologist in private practice in Ohio. He has strong expertise in clinical research in all aspects of rheumatology. He is also a thought leader in the field of osteoporosis. He has published many articles on rheumatoid arthritis and osteopoprosis and speaks to both community...

View All GLG Leaders in Healthcare

GLG Study Groups in Healthcare(?)

Study Group Name	Members
Oncologists (US)	2254
Pharmacists (US)	2075
Obstetricians/Gynecologists	1819
Neurologists	1776
Pediatricians (US)	1639

View All Study Groups in Healthcare

GLG News^SM Analyses in Healthcare(?)

Requires a subscription to GLG News

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Yes - please stop the cycle of 70 deaths then pull the drug! | 07-03-2008
Analysis of: Drug Makers Say FDA Safety Focus Is Slowing New-Medicine Pipeline | online.wsj.com
Author: GLG Expert Contributor

Drugs are released to the market without adequate study, then, after around 70 to 100 patient deaths due to the drug are reported, the drug is pulled from the market. Getting in front of this "problem" would improve the safety of our drug supply.

An illegal use of Lumigan, now legal? | 07-03-2008

Analysis of: Longer Lashes in a Tube? Maybe Not | www.nytimes.com

Author: Steve Rubinstein, OD, Optometrist, Sound Shore Vision Care

A few months ago, a small company tried to import Lumigan (bimatoprost), licensed by Allergan, in an eyelash applicator. It was held by the FDA as an unapproved use of a prescription medication. Now the owner of the patent is trying to import the same drug legally.

why are we going backwards | 07-03-2008
Analysis of: FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler | www.investor.jnj.com
Author: GLG Expert Contributor

makes no sense to introduce a product that does not last as long as others on the market unless you are going t sell it to the patient at a substantial prce savings. Even in that scenario, needle fatigue wil eventually make the patient seek a different filler.

Lung cancer profiling- May lead to improvements in care! Implications for Genentech & others. | 07-03-2008

Analysis of: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells | content.nejm.org

Author: Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC

We may be able to analyze EGFR mutations from periperal blood of lung cancer patients. Very frequently enough tissue fromm needle biopsies are not available for analysis. This may replace the need for new biopsies.

One Drug, Many Uses -- Mostly a Very Good Idea | 07-03-2008

Analysis of: One drug, many uses. Good idea? | www.indystar.com

Author: Louis Sanfilippo, MD, Psychiatrist, Louis Sanfilippo, MD

‘One drug, many uses’ can make lots of sense clinically and commercially. Seeking additional FDA indications for a specific drug has obvious business benefits: greater revenue stream, improved branding, potentially longer market exclusivity, greater franchising potential of the drug...

View All GLG News in Healthcare